The firm said that immunoassays had 19 years in a row of double-digit growth, driven in part by an automated workflow approach to achieving lab efficiencies.
The CE-marked test enables health professionals to distinguish between HIV-1 and HIV-2, and runs on the fully automated Cobas 6800/8800 systems.
The test, which simultaneously detects MRSA and Staphylococcus aureus, is designed to run on the company's Liat PCR point-of-care platform.
Enzo's patent relates to modified nucleotides for diagnostic and therapeutic applications, and is central to separate ongoing lawsuits with diagnostic developers.
The company said that it has had interest so far in its focused Avenio kits as well as larger panels for surveillance and monitoring.
The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.
Roche's Bluetooth-enabled meter gives patients the option to bypass frequent trips to the clinic in favor of doing anticoagulation testing at home.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
In a recent regulatory filing, Thermo disclosed that it acquired Core Informatics for $94 million and Finesse Solutions for $220 million.
The Ventana PD-L1 assay was approved as a complementary diagnostic for bladder cancer patients being considered for treatment with the immunotherapy Imfinzi.
Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.
The New York Times reports on the shifting interpretations of what some genetic variants mean over time.
In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.
MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.